All patients should have the appropriate medical history and physical examination performed by a qualified health care practitioner.
- Baseline Investigations
- Stage 0: bilateral mammography
- Stage I: bilateral mammography and laboratory investigations*
- Stage II: bilateral mammography, chest x-ray, laboratory investigations*, and optional abdominal imaging
- Stage III: bilateral mammography, chest x-ray or chest computed tomography (CT)†, abdominal imaging (ultrasound [U/S] or CT†), bone scan, and laboratory investigations*
- Stage IV: chest x-ray or chest CT†, abdominal imaging (U/S or CT†), bone scan, and laboratory investigations*
- Unless metastatic disease is suspected from symptoms and/or physical exam, staging tests can be performed after surgery.
- All baseline investigations (see Figure 1 in the original guideline document), as per this guideline, will be reviewed at the cancer centre.
- Investigations Prior to Adjuvant Chemotherapy
- For anthracycline-based chemotherapy (e.g., lymph node positive patients): multigated radionuclide angiography (MUGA) or echocardiogram (ECHO)
- For trastuzumab (e.g., human epidermal growth factor receptor 2 [HER2+] patients): MUGA or ECHO
- For adjuvant chemotherapy (e.g., lymph node positive patients, high risk, lymph node negative patients, stage III patients, or stage IV patients): laboratory investigations*
- Baseline cardiac investigations (if required) for subsequent adjuvant therapy can be arranged at the time of the cancer centre triage review.
- Tumour, Node, Metastasis (TNM) Classification
- The TNM staging system developed by the American Joint Committee on Cancer (Edge et al., 2010) is used to group patients with respect to prognosis. TNM staging definitions are included in Appendix A of the original guideline document.
*Laboratory investigations include complete blood count (CBC), creatinine, aspartate aminotransferase/alanine aminotransferase (AST/ALT), alkaline phosphatase (AP), total bilirubin, albumin, calcium, and lactate dehydrogenase (LDH).
†CT is preferred for inflammatory breast cancer.
An algorithm for the staging of asymptomatic and newly diagnosed breast cancer is provided in the original guideline document.
Asymptomatic and newly diagnosed breast cancer
Obstetrics and Gynecology
Advanced Practice Nurses
Allied Health Personnel
To provide recommendations that outline which tests should be included in the staging investigation of patients with asymptomatic, biopsy confirmed breast cancer, in an effort to standardize clinical practice across the province and to expedite the subsequent assessment and treatment of patients in the cancer centres
Patients with asymptomatic, biopsy-confirmed breast cancer, prior to referral to the cancer centre
- Medical history and physical examination
- Baseline investigations based on stage
- Bilateral mammography
- Laboratory investigations
- Chest x-ray or chest computed tomography (CT)
- Abdominal imaging (ultrasound or CT)
- Bone scan
- Investigations prior to adjuvant chemotherapy
- Multigated radionuclide angiography (MUGA) or echocardiogram (ECHO)
- Laboratory investigations
- Tumour, Node, Metastasis (TNM) classification
- Positive predictive value and negative predictive value of breast cancer staging tests
- Incremental cancer detection rate (ICDR)
- Reoperation rates
- Presence of metastases
- Detection of metastases
Searches of Electronic Databases
Specific research questions to be addressed by the guideline document were formulated by the guideline lead(s) and Knowledge Management (KM) Specialist using the PICO question format (patient or population, intervention, comparisons, outcomes).
- What are the appropriate staging investigations (e.g., imaging and blood work) for patients with asymptomatic, newly biopsy-confirmed breast cancer?
- Do staging investigations vary according to stage of disease or other factors at diagnosis?
A systematic search for clinical practice guidelines, systematic reviews, meta-analyses, and clinical studies was conducted of: MEDLINE, EMBASE, the Cochrane Library, Cancerview, and the National Guideline Clearinghouse. The search terms included "breast cancer" and "staging investigations." The search covered the period between 1965 and April 18, 2011. A total of seven clinical practice guidelines, one meta-analysis, and 10 clinical studies were deemed relevant.
In April 2012, the American Society of Clinical Oncology published five practices or interventions that are widely used, but not supported by high-level clinical evidence. The recommendation against performing positron emission tomography (PET), computed tomography (CT), and radionuclide bone scans in the staging of early breast cancer at low risk for metastasis has been added to this guideline.
Systematic Review with Evidence Tables
Evidence was selected and reviewed by a working group comprised of members from the Alberta Provincial Breast Tumour Team and a Knowledge Management (KM) Specialist from the Guideline Utilization Resource Unit (GURU). A detailed description of the methodology followed during the guideline development process can be found in the Guideline Utilization Resource Unit Handbook (see the "Availability of Companion Documents" field).
Evidence tables containing the first author, year of publication, patient group/stage of disease, methodology, and main outcomes of interest are assembled using the studies identified in the literature search. Existing guidelines on the topic are assessed by the KM Specialist using portions of the AGREE II (http://www.agreetrust.org/ ) instrument and those meeting the minimum requirements are included in the evidence document. Due to limited resources, GURU does not regularly employ the use of multiple reviewers to rank the level of evidence; rather, the methodology portion of the evidence table contains the pertinent information required for the reader to judge for himself the quality of the studies.
Evidence tables, summarizing the information from the 18 sources, are included in Appendix B of the original guideline document.
The working group members formulate the guideline recommendations based on the evidence synthesized by the Knowledge Management (KM) Specialist during the planning process, blended with expert clinical interpretation of the evidence. As detailed in the Guideline Utilization Resource Unit Handbook (see the "Availability of Companion Documents" field), the working group members may decide to adopt the recommendations of another institution without any revisions, adapt the recommendations of another institution or institutions to better reflect local practices, or develop their own set of recommendations by adapting some, but not all, recommendations from different guidelines.
The degree to which a recommendation is based on expert opinion of the working group and/or the Provincial Tumour Team members is explicitly stated in the guideline recommendations. Similar to the American Society of Clinical Oncology (ASCO) methodology for formulating guideline recommendations, the Guideline Utilization Resource Unit (GURU) does not use formal rating schemes for describing the strength of the recommendations, but rather describes, in conventional and explicit language, the type and quality of the research and existing guidelines that were taken into consideration when formulating the recommendations.
The guideline development panel, including medical oncologists, radiation oncologists, and breast surgeons, initially reviewed the evidence in between May 2010 and October 2010. A draft document was subsequently developed, distributed for review, and discussed with the Breast Tumour Team at the annual meeting in January 2011. After a review of existing guidelines and clinical consensus, recommendations were agreed upon.
The guideline developers reviewed published cost analyses.
Internal Peer Review
This guideline was reviewed and endorsed by the Alberta Provincial Breast Tumour Team.
When the draft guideline document is completed, revised, and reviewed by the Knowledge Management Specialist and the working group members, it is sent to all members of the Provincial Tumour Team for review and comment. The working group members then make final revisions to the document based on the received feedback, as appropriate. Once the guideline is finalized, it is officially endorsed by the Provincial Tumour Team Lead and the Executive Director of Provincial Tumour Programs.
|Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editor(s). AJCC cancer staging manual. 7th ed. New York (NY): Springer; 2010.|
The type of evidence supporting the recommendations is not specifically stated.
Appropriate staging investigations in patients with newly diagnosed breast cancer can aid in expediting care at the tertiary and associate cancer centres.
False-positive results of staging investigations
The recommendations contained in this guideline are a consensus of the Alberta Provincial Breast Tumour Team and represent a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.
- Present the guideline at the local and provincial tumour team meetings and weekly rounds.
- Post the guideline on the Alberta Health Services website.
- Send an electronic notification of the new guideline to all members of Alberta Health Services, Cancer Care.
|Alberta Provincial Breast Tumour Team. Staging investigations for asymptomatic and newly diagnosed breast cancer. Edmonton (Alberta): Alberta Health Services, Cancer Care; 2012 Jul. 17 p. (Clinical practice guideline; no. BR-012). [30 references]|
Not applicable: The guideline was not adapted from another source.
CancerControl Alberta - State/Local Government Agency [Non-U.S.]
Alberta Health Services, Cancer Care
Alberta Provincial Breast Tumour Team
Participation of members of the Alberta Provincial Breast Tumour Team in the development of this guideline has been voluntary and the authors have not been remunerated for their contributions. There was no direct industry involvement in the development or dissemination of this guideline. Alberta Health Services, Cancer Care recognizes that although industry support of research, education and other areas is necessary in order to advance patient care, such support may lead to potential conflicts of interest. Some members of the Alberta Provincial Breast Tumour Team are involved in research funded by industry or have other such potential conflicts of interest. However the developers of this guideline are satisfied it was developed in an unbiased manner.
This is the current release of the guideline.
Electronic copies: Available in Portable Document Format (PDF) from the Alberta Health Services Web site .
The following is available:
- Guideline utilization resource unit handbook. Edmonton (Alberta): Alberta Health Services, Cancer Care; 2011 Dec. 5 p. Electronic copies: Available in Portable Document Format (PDF) from the Alberta Health Services Web site .
This NGC summary was completed by ECRI Institute on December 6, 2012. The information was verified by the guideline developer on January 14, 2013.
This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.
The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.
All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.
Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion-criteria.aspx.
NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.
Readers with questions regarding guideline content are directed to contact the guideline developer.